Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Breast cancer prognosis test offers patient benefits as part of personalised treatment strategy

Agendia : 17 December, 2007  (New Product)
Agendia’s MammaPrint breast cancer prognosis test has been successfully implemented in the diagnostic process of breast cancer patients in community hospitals in The Netherlands.
MammaPrint assigned up to one third of the patients to different risk categories as compared to currently used risk assessment tools. In the majority of these situations, it may lead to a reduction in the use of adjuvant chemotherapy. The findings were published in the December issue of The Lancet Oncology.

In the study, breast tumours from 585 patients with lymph node-negative, invasive breast cancer, collected at 16 hospitals in The Netherlands. Fresh samples were shipped in RNAretain at ambient temperature and were subjected at Agendia Laboratories to MammaPrint gene expression analysis.

Results were available for 427 patients. Patients were classified as having either a poor prognosis (high risk for distant metastasis) or good prognosis (low risk for metastasis). The results were then compared by the study coordinators to risk assessments of commonly used guidelines, including the Dutch Institute for Health Improvement (Dutch CBO) Guidelines, St Gallen Guidelines, Nottingham Prognostic Index, and Adjuvant Online. Many guidelines use algorithms (based on the patient's age, tumour size, and node status) to determine a patient's prognosis and determine whether or not patients should receive chemotherapy.

'More than 70 percent of patients who have node-negative breast cancer are successfully treated without chemotherapy. Identifying which patients with breast cancer will most likely require adjuvant chemotherapy is an important step in personalising a patient's treatment regimen, and ensuring that patients aren't receiving unnecessary treatment,' said Dr Laura van 't Veer, chief research officer at Agendia, who participated in the study.

Adjuvant chemotherapy was advised less often when the patient's prognosis was based on the Dutch CBO Guidelines - which are considered the most restrictive - compared with assessments based on MammaPrint. For the other guidelines assessed, however, less adjuvant therapy would be given based on the prognosis of MammaPrint. The results confirm previous findings and validations with the test.

'These data provide important information to patients and physicians that can effectively help guide treatment decisions in community-based hospitals. The prognosis provided by MammaPrint, together with guidance from clinical guidelines and patients' treatment preferences, are vital tools for physicians caring for breast cancer patients,' said Bernhard Sixt, chief executive officer at Agendia.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo